IRCT20190303042905N2 IRCT 2021-01-31 Ahvaz University of Medical Sciences Effect of butyrate in obesity The Effects of butyrate supplementation on the expression levels of PGC-1α, PPARα and UCP1 genes, serum level of GLP-1, metabolic parameters, and anthropometric indices in obese individuals on a weight loss diet: A Triple- Blind, Randomized, Placebo- Controlled Clinical Trial. 2021-03-21 anticipated 50 Complete https://irct.ir/trial/53968 interventional Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Based on inclusion criteria, 50 patients will randomly allocated to placebo (n = 25) or intervention (n = 25) groups. Block design based on the combined analysis and using packed envelopes is used for randomization. In fact, according to the pattern and using two codes of A and B 6 groups with 4 blocks are selected. This work is repeated in 2 steps. In the end, two A and B codes are assigned to the 2 last patients and the randomization is completed (50 patients), Blinding description: The researchers and patients will not inform of the contents of the packets. A third person of health care does the coding. This person will not aware of the details of the research trial. 2 Obesity. Intervention 1: Intervention group: one butyrate capsule of 600mg/day (made by Body Bio company, USA, containing 550 mg of butyrate and 50 mg sodium hydroxide, medium-chain triglycerides (MCT), hydroxypropyl methylcellulose, and purified water) for 60 days. Intervention 2: Control group: one placebo capsule of 600 mg/day (compounds similar to supplement except for butyrate) for 60 days. No - There is not a plan to make this available Justification or reason for not sharing IPD is The person's information will be confidential and the results will be as collective statistics